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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
increasing maternal folate status by supplemental folate intake and reduced 




EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Rank Nutrition Ltd, submitted for authorisation of a health claim pursuant to 
Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to increasing maternal folate status by supplemental folate intake and 
reduced risk of neural tube defects. The Panel considers that the food constituent, supplemental folate, which is 
the subject of the claim, is sufficiently characterised. Increasing maternal folate status by supplemental folate 
intake is a beneficial physiological effect in the context of reducing the risk of neural tube defects. In weighing 
the evidence, the Panel took into account that the association between low maternal folate intakes and an 
increased risk of neural tube defects is well established, and that a recent systematic review showed an effect of 
maternal folic acid intakes on the risk of neural tube defects. The Panel concludes that a cause and effect 
relationship has been established between increasing maternal folate status by supplemental folate intake and a 
reduced risk of neural tube defects. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Rank Nutrition Ltd, submitted for authorisation of a health claim 
pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the United 
Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver 
an opinion on the scientific substantiation of a health claim related to increasing maternal folate status 
by supplemental folate intake and reduced risk of neural tube defects (NTD). 
The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction.  
The food constituent that is the subject of the health claim is folic acid. Folic acid is used as synthetic 
folate in food supplements and in food fortification because of its stability, and becomes biologically 
active after reduction. Folate is the generic name for this B-vitamin and different forms of folate are 
authorised for addition to foods (Annex II of Regulation (EC) No 1925/2006 and Annex II of 
Directive 2002/46/EC). This evaluation applies to all forms of folate authorised for addition to foods 
(Annex II of the Regulation (EC) No 1925/2006 and Annex II of Directive 2002/46/EC).  
The Panel considers that the food constituent, supplemental folate, which is the subject of the health 
claim, is sufficiently characterised.  
The claimed effect proposed by the applicant is “protective effect of folic acid against neural tube 
defects in the foetus, through beneficially raising maternal red blood cell folate”. The target population 
proposed by the applicant is women of child-bearing age. The Panel considers that increasing maternal 
folate status by supplemental folate intake is a beneficial physiological effect in the context of 
reducing the risk of NTD. 
In weighing the evidence, the Panel took into account that the association between low maternal folate 
intakes and an increased risk of NTD is well established, and that a recent systematic review showed 
an effect of maternal folic acid intakes on the risk of NTD. 
The Panel concludes that a cause and effect relationship has been established between increasing 
maternal folate status by supplemental folate intake and a reduced risk of NTD. 
The Panel considers that the following wording reflects the scientific evidence: “Supplemental folate 
intake increases maternal folate status. Increasing maternal folate status contributes to the reduction of 
the risk of NTD.” 
The Panel considers that in order to obtain the claimed effect 400 μg supplemental folate should be 
consumed daily for at least one month before and up to three months after conception. The target 
population is women of child-bearing age. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of permitted 
claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 25/02/2013. 
 The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction.  
 On 30/04/2013, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 30/05/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 13/06/2013. 
 During its meeting on 10/07/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to increasing 
maternal folate status by supplemental folate intake and reduced risk of neural tube defects. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on 
the scientific substantiation of a health claim related to increasing maternal folate status by 
supplemental folate intake and reduced risk of neural tube defects. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of supplemental folate, a positive assessment of its safety, nor a decision on whether supplemental 
folate is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen 
in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
  
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Rank Nutrition Ltd, Long Barn, Etchden Court, Bethersden, Kent 
TN26 3DP, United Kingdom. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent, which is the subject of the claim, is folic acid. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect relates to the protective effect of folic acid against 
neural tube defects in the foetus, through beneficially raising maternal red blood cell folate. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Folic acid supplementation 
raises maternal red blood cell folate. Low maternal red blood cell folate is a risk factor for neural tube 
defects in the developing foetus”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, information should be given to the consumer that the beneficial effect is 
observed with a daily intake of 400 micrograms folic acid per day taken as a dietary supplement at 
least 12 weeks prior to conception and during the first 12 weeks of pregnancy. The target population 
proposed by the applicant is all women of child-bearing age. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is folic acid.  
Folic acid is used as synthetic folate in food supplements and in food fortification because of its 
stability, and becomes biologically active after reduction (SCF, 2000).  
Folate is the generic name for this B-vitamin and different forms of folate are authorised for addition 
to foods (Annex II of Regulation (EC) No 1925/2006
5
 and Annex II of Directive 2002/46/EC
6
). This 
evaluation applies to all forms of folate authorised for addition to foods (Annex II of Regulation (EC) 
No 1925/2006 and Annex II of Directive 2002/46/EC).  
The Panel considers that the food constituent, supplemental folate, which is the subject of the health 
claim, is sufficiently characterised.  
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “protective effect of folic acid against neural tube 
defects in the foetus, through beneficially raising maternal red blood cell folate”. The target population 
proposed by the applicant is women of child-bearing age. 
Neural tube defects (NTD) are the most common congenital malformations of the central nervous 
system resulting from fusion failure of the caudal neural tube (Román, 2006) up to 8-10 weeks of 
embryonic life. Some of these malformations are incompatible with life (anencephaly) and others 
(spina bifida) result in various disabilities. 
                                                     
5  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
6  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
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While folate in serum or plasma is a sensitive marker of early changes in folate status (Herbert, 1987), 
red blood cell (RBC) folate is considered a reliable biomarker of long-term folate status as it reflects 
tissue folate stores (Wu et al., 1975) and decreases only weeks or months after the initial reduction of 
folate intake and the fall of serum folate concentrations (Eichner and Hillman, 1973).  
The Panel considers that increasing maternal folate status by supplemental folate intake is a beneficial 
physiological effect in the context of reducing the risk of NTD. 
3. Scientific substantiation of the claimed effect 
There is consensus that low folate intakes are associated with an increased risk of NTD and that 
women of child-bearing age should consume supplemental folic acid at a level of 400 μg per day for at 
least one month before and up to three months after conception, in addition to consuming food folate 
from a varied diet in order to reduce the risk of NTD (IoM, 1998; NHMRC, 2006; SACN, 2006; D-A-
CH, 2013). 
This consensus is in line with a recent systematic review and meta-analysis (De-Regil et al., 2010) 
which included six randomised and quasi-randomised trials (Laurence et al., 1981; MRC Vitamin 
Study Research Group, 1991; Czeizel and Dudas, 1992; Kirke et al., 1992; Czeizel et al., 1994; Indian 
Council of Medical Research, 2000) in women who became or were <12 weeks pregnant at the time of 
the intervention and in which supplemental folic acid was administered vs. no treatment, placebo or 
other micronutrients without folic acid on the risk of occurrence or reoccurrence of NTD. These 
studies evaluated a total 3 066 births in the intervention and 3 039 births in the control groups, with 12 
occurrences of NTD in the intervention and 45 occurrences in the control arms. Using a fixed effects 
model, the relative risk (RR) of NTD in the intervention arms was statistically significantly lower as 
compared to the control arms (mean RR 0.28 (95 % CI 0.15 to 0.52)).  
In weighing the evidence, the Panel took into account that the association between low maternal folate 
intakes and an increased risk of NTD is well established, and that a recent systematic review showed 
an effect of maternal folic acid intakes on the risk of NTD. 
The Panel concludes that a cause and effect relationship has been established between increasing 
maternal folate status by supplemental folate intake and a reduced risk of NTD. 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “Supplemental folate 
intake increases maternal folate status. Increasing maternal folate status contributes to the reduction of 
the risk of NTD.” 
5. Conditions and restrictions of use  
The Panel considers that in order to obtain the claimed effect, 400 μg supplemental folate should be 
consumed daily for at least one month before and up to three months after conception. The target 
population is women of child-bearing age. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, supplemental folate, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect proposed by the applicant is “protective effect of folic acid against neural 
tube defects in the foetus, through beneficially raising maternal red blood cell folate”. The 
target population proposed by the applicant is women of child-bearing age. Increasing 
Increasing maternal folate status by supplemental folate intake  
and reduced risk of neural tube defects 
 
 
7 EFSA Journal 2013;11(7):3328 
maternal folate status by supplemental folate intake is a beneficial physiological effect in the 
context of reducing the risk of NTD. 
 A cause and effect relationship has been established between increasing maternal folate status 
by supplemental folate intake and a reduced risk of NTD. 
 The following wording reflects the scientific evidence: “Supplemental folate intake increases 
maternal folate status. Increasing maternal folate status contributes to the reduction of the risk 
of NTD.” 
 In order to obtain the claimed effect, 400 μg supplemental folate should be consumed daily for 
at least one month before and up to three months after conception. The target population is 
women of child-bearing age. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application related to increasing maternal folate status by supplemental folate intake and 
reduced risk of neural tube defects pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim 
serial No: 0379_UK). May 2013. Submitted by Rank Nutrition Ltd. 
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GLOSSARY AND ABBREVIATIONS 
NTD  Neural tube defects  
RBC Red blood cell 
